The latest in research news, as gathered by Debbie Rigby
This article reviews the pharmacokinetic and pharmacodynamic properties of the sofosbuvir plus ledipasvir (SOF/LDV) fixed dose combination for the treatment of hepatitis C virus (HCV). The SOF/LDV fixed dose combination has good pharmacological properties that lead to a high sustained virological response after 12 or 24 weeks of treatment. There is minimal interference with other drugs or associated renal or hepatic impairment, such that dose adjustment is not necessary.
Expert Opinion on Drug Metabolism & Toxicology, posted online: 31 Oct 2016
A systematic review from 28 trials (only three of which were placebo-controlled) shows high-strength evidence that colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids reduce pain in patients with acute gout. It also showed that low-dose colchicine is as effective as high-dose colchicine and causes fewer gastrointestinal adverse events. Urate-lowering therapy (allopurinol or febuxostat) decreases serum urate levels and reduces risk for acute gout attacks.
Ann Intern Med. 2016.
These guidelines recommend that clinicians choose corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or colchicine to treat patients with acute gout. ACP recommends against initiating long-term urate–lowering therapy in most patients after a first gout attack or in patients with infrequent attacks. The guidelines also recommend a patient-centred approach to discuss benefits, harms, costs, and individual preferences with patients before initiating urate-lowering therapy, including concomitant prophylaxis, in patients with recurrent gout attacks.
Ann Intern Med. 2016.
This study conducted in the Netherlands explored how pharmacists and pharmacy technicians communicate about ICS with patients with asthma and/or chronic obstructive pulmonary disease, what topics are discussed by them, and whether pharmacists and pharmacy technicians differ in their communication during counseling sessions. The authors concluded that more attention to ICS adherence, lifestyle, and psychosocial topics may be needed.
Patient Preference and Adherence 2016:10 2239–2254.